A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice

Alcohol use disorder (AUD) affects over 18 million people in the US. Unfortunately, pharmacotherapies available for AUD have limited clinical success and are under prescribed. Previously, we established that avermectin compounds (ivermectin [IVM] and moxidectin) reduce alcohol (ethanol/EtOH) consumption in mice, but these effects are limited by P-glycoprotein (Pgp/ABCB1) efflux. The current study tested the hypothesis that dihydromyricetin (DHM), a natural product suggested to inhibit Pgp, will enhance IVM potency as measured by changes in EtOH consumption. Using a within-subjects study design and two-bottle choice study, we tested the combination of DHM (10 mg/kg; i.p.) and IVM (0.5–2.5 mg/kg; i.p.) on EtOH intake and preference in male and female C57BL/6J mice. We also conducted molecular modeling studies of DHM with the nucleotide-binding domain of human Pgp that identified key binding residues associated with Pgp inhibition. We found that DHM increased the potency of IVM in reducing EtOH consumption, resulting in significant effects at the 1.0 mg/kg dose. This combination supports our hypothesis that inhibiting Pgp improves the potency of IVM in reducing EtOH consumption. Collectively, we demonstrate the feasibility of this novel combinatorial approach in reducing EtOH consumption and illustrate the utility of DHM in a novel combinatorial approach.     

Solvothermal Synthesis of Multiple Dihydropyrimidinones at a Time as Inhibitors of Eg5

Solvothermal synthesis of multiple dihydropyrimidinones at a time has been developed in inexpensive and green bio-based solvent lactic acid without any additional catalysts or additives. By this method, thirty new dihydropyrimidinone derivatives were synthesized in two batches and characterized. All of the compounds were screened by Eg5 motor protein ATPase assay, and the positive compounds were tested against the Caco-2 cell line, HeLa cell line, L929 cell line and T24 cell line in vitro. Among them, compound C9 exhibited the best inhibitory activity against motor protein ATPase with an IC₅₀ value of 30.25 μM and significant cytotoxic activity in the micromolar range against the cells above. The Lineweaver–Burk plot revealed that compound C9 was a mixed-type Eg5 inhibitor. A molecular modeling study using the Discovery Studio program was performed, where compound C9 exhibited good binding interaction with Eg5 motor protein ATPase, and this was consistent with the attained experimental results.     

Prodigiosin of Serratia marcescens ZPG19 Alters the Gut Microbiota Composition of Kunming Mice

Prodigiosin is a red pigment produced by Serratia marcescens with anticancer, antimalarial, and antibacterial effects. In this study, we extracted and identified a red pigment from a culture of S. marcescens strain ZPG19 and investigated its effect on the growth performance and intestinal microbiota of Kunming mice. High-performance liquid chromatography/mass spectrometry revealed that the pigment had a mass-to-charge ratio (m/z) of 324.2160, and thus it was identified as prodigiosin. To investigate the effect of prodigiosin on the intestinal microbiota, mice (n = 5) were administered 150 μg/kg/d prodigiosin (crude extract, 95% purity) via the drinking water for 18 days. Administration of prodigiosin did not cause toxicity in mice. High-throughput sequencing analysis revealed that prodigiosin altered the cecum microbiota abundance and diversity; the relative abundance of Desulfovibrio significantly decreased, whereas Lactobacillus reuteri significantly increased. This finding indicates that oral administration of prodigiosin has a beneficial effect on the intestinal microbiota of mice. As prodigiosin is non-toxic to mouse internal organs and improves the mouse intestinal microbiota, we suggest that it is a promising candidate drug to treat intestinal inflammation.     

Four New Gallate Derivatives from Wine-Processed Corni Fructus and Their Anti-Inflammatory Activities

Four new gallate derivatives—ornusgallate A, ent-cornusgallate A, cornusgallate B and C (1a, 1b, 2, 3)—were isolated from the wine-processed fruit of Cornus officinalis. Among them, 1a and 1b are new natural compounds with novel skeletons. Their chemical structures were elucidated by comprehensive spectroscopy methods including NMR, IR, HRESIMS, UV, ECD spectra and single-crystal X-ray diffraction analysis. The in vitro anti-inflammatory activities of all compounds were assayed in RAW 264.7 cells by assessing LPS-induced NO production. As the result, all compounds exhibited anti-inflammatory activities at attested concentrations. Among the tested compounds, compound 2 exhibited the strongest anti- inflammatory activity.     

锂金属电池用高浓度电解液体系研究进展

锂金属二次电池具有极高的能量密度,是下一代储能电池的研究热点。然而,金属锂负极在传统碳酸酯电解液1 mol·L^?1 LiPF6-EC/DEC(ethylene carbonate/diethyl carbonate)中充放电时,存在严重的枝晶生长和循环效率低下等问题,阻碍了其商业化应用。因此,开发与锂负极兼容的新型电解液体系是目前重要的研究任务。与传统稀溶液相比,高浓度电解液体系具有独有的物化性质和优异的界面相容性,并且能有效抑制锂枝晶生长、显著提升锂负极的循环可逆性,因而格外受到关注。本文综述了高浓度电解液及局部高浓电解液体系的最新研究进展,分析了其溶液化学结构和物化性质,对其与锂负极的界面相容性、枝晶抑制效果、效率提升能力及界面稳定性机制进行了探讨;文章着重介绍了高浓与局部高浓电解液体系在锂金属二次电池中的应用,同时从基础科学研究和应用研究两个层面对高浓电解液和局部高浓电解液存在的主要问题进行了简要分析,并对其未来发展方向进行了展望。     

锂金属负极人造保护膜的研究进展

金属锂因其具有极高的理论容量(3860 mAh·g^?1)、最低的电极电位(?3.04 V vs.标准氢电极)和低的密度(0.534 g·cm^?3),被认为是最具潜力的负极材料。但循环过程中不可控的枝晶生长及不稳定的固体电解质相界面膜所引起的安全隐患和电池库伦效率低等问题严重阻碍了锂金属负极的发展。通过在电极表面构建人造保护膜可以有效调控锂离子沉积行为,因此人造保护膜的构建是一种简单高效抑制锂枝晶生长的策略。本综述将从聚合物保护膜、无机保护膜、有机-无机复合保护膜和合金保护膜总结了人造保护膜的构建方法、抑制锂枝晶生长机理,为促进高比能锂金属电池的商业化应用提供借鉴参考作用。     

溶液法生长大面积超薄钙钛矿单晶薄膜

卤化物钙钛矿由于其独特的光电性质,在薄膜光电子器件领域具有极大潜力1。虽然许多工作都集中在多晶钙钛矿材料上,但单晶钙钛矿比多晶具有更低的缺陷态密度、更好的载流子输运能力和更高的稳定性2,3,可以有有效减少甚至消除载流子输运过程中的散射损失以及在晶界处的非辐射性复合4。采用单晶钙钛矿薄膜作为器件活性层被认为是进一步提高钙钛矿光电子器件性能的理想方案。目前,研究报道的钙钛矿单晶薄膜生长方法主要通过化学气相沉积和溶液空间限制法5,6,然而,所制备的薄膜厚度往往较厚,相应的器件性能也没有多晶薄膜的器件高7,因此,生长高质量的超薄大面积钙钛矿单晶薄膜至关重要。     

高力学强度细菌纤维素气凝胶纤维的连续化制备

气凝胶纤维因其高外表面积和高柔韧性在能量管理系统中具有潜在应用而引起了广泛关注.但是,目前制备的气凝胶纤维力学强度较低,限制了其实际应用.为提高气凝胶纤维力学性能,在始终保持细菌纤维素(BC)纳米纤维处于湿态下,利用NaOH/尿素/硫脲复合溶剂直接低温溶解原生BC,获得透明的BC纺丝原液;通过湿法纺丝制备了BC水凝胶纤维,经过水洗和冷冻干燥后处理,制得BC气凝胶纤维.采用偏光显微镜(POM)、13C核磁共振(13C-NMR)和高级旋转流变仪研究BC在复合溶剂中的溶解过程与状态;利用全反射傅里叶变换红外吸收光谱(ATR-FTIR)、X射线衍射(XRD)和热失重(TG)研究BC溶解前后结构与性能变化;利用场发射扫描电镜(FESEM)、全自动比表面积和孔径分布分析仪、单丝强力仪对获得的BC气凝胶纤维结构与性能进行表征.结果表明,复合溶剂在?15℃条件下可以直接溶解原生湿态BC,最高溶解浓度为3 wt%;采用湿法纺丝制得高度多孔的连续BC气凝胶纤维,比表面积高达192 m^2/g且具有优异的力学性能,断裂强度和杨氏模量高达(9.36±1.68)MPa和(176±17.55)MPa,如0.4 mg BC气凝胶纤维可以支撑高于其本身质量5×10^4倍的重物.     

在体酶生物燃料电池的研究进展

酶生物燃料电池(Enzymatic biofuel cells,EBFCs)具有高专一性和催化性能,可催化与氧化还原反应有关的燃料并获得电能.可用的生物燃料,如葡萄糖、乳酸和丙酮酸盐,可以从汗液、泪液和血液中提取,因而以体液为燃料的EBFCs在可植入式或可穿戴式设备中具有良好的应用前景.采用生物电催化机理对酶生物燃料电池在体液发电中的应用进行了研究,以及对可植入式或可穿戴式生物燃料电池的主要挑战和未来的前景进行了展望.